Quanterix , a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced an alliance with PBL Assay Science (PBL), naming the Company as a Preferred Partner for assay research and development.
Leveraging Simoa’s sensitivity and revolutionary digital approach for assay development and research, PBL will have the ability to enter new markets and strengthen its current offerings.
As a leading provider of products, services, information, and know-how related to interferons, cytokines, antibodies, ELISAs, and assay solutions, PBL Assay Science is working hand in hand with industry, academic and government researchers to solve difficult assay development and protein quantification problems for its customers.
Using Simoa’s single molecule detection capabilities, PBL will be able to provide their customers with a completely automated experience, ensuring consistent results and the greatest sensitivity possible.
"PBL’s alliance with Quanterix is a natural fit for our companies. Incorporating Simoa’s ultrasensitive single molecule measurement into our pipeline of assay development and services capabilities allows us to enter new markets and significantly strengthen current offerings," said Dr. Thomas Lavoie, Chief Scientific Officer, PBL.
PBL Assay Science is a major provider of products, services, information, and know-how related to interferons, cytokines, antibodies, ELISAs, and assay solutions.